1. Home
  2. PUK vs BGNE Comparison

PUK vs BGNE Comparison

Compare PUK & BGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PUK
  • BGNE
  • Stock Information
  • Founded
  • PUK 1848
  • BGNE 2010
  • Country
  • PUK Hong Kong
  • BGNE Cayman Islands
  • Employees
  • PUK N/A
  • BGNE N/A
  • Industry
  • PUK Life Insurance
  • BGNE Biotechnology: Pharmaceutical Preparations
  • Sector
  • PUK Finance
  • BGNE Health Care
  • Exchange
  • PUK Nasdaq
  • BGNE Nasdaq
  • Market Cap
  • PUK 22.3B
  • BGNE 21.0B
  • IPO Year
  • PUK 1990
  • BGNE 2016
  • Fundamental
  • Price
  • PUK $15.94
  • BGNE $190.51
  • Analyst Decision
  • PUK
  • BGNE Buy
  • Analyst Count
  • PUK 0
  • BGNE 7
  • Target Price
  • PUK N/A
  • BGNE $247.07
  • AVG Volume (30 Days)
  • PUK 1.4M
  • BGNE 302.8K
  • Earning Date
  • PUK 08-28-2024
  • BGNE 11-12-2024
  • Dividend Yield
  • PUK 2.64%
  • BGNE N/A
  • EPS Growth
  • PUK N/A
  • BGNE N/A
  • EPS
  • PUK 0.32
  • BGNE N/A
  • Revenue
  • PUK $10,944,000,000.00
  • BGNE $3,351,304,621.00
  • Revenue This Year
  • PUK N/A
  • BGNE $969.39
  • Revenue Next Year
  • PUK $11.71
  • BGNE $24.79
  • P/E Ratio
  • PUK $24.11
  • BGNE N/A
  • Revenue Growth
  • PUK N/A
  • BGNE 50.22
  • 52 Week Low
  • PUK $15.11
  • BGNE $126.97
  • 52 Week High
  • PUK $23.37
  • BGNE $248.16
  • Technical
  • Relative Strength Index (RSI)
  • PUK 41.14
  • BGNE 36.79
  • Support Level
  • PUK $15.70
  • BGNE $184.49
  • Resistance Level
  • PUK $16.13
  • BGNE $198.48
  • Average True Range (ATR)
  • PUK 0.25
  • BGNE 5.94
  • MACD
  • PUK -0.01
  • BGNE -0.65
  • Stochastic Oscillator
  • PUK 33.33
  • BGNE 23.61

About PUK Prudential Public Limited Company

Originally established as Prudential Mutual Assurance, Investment, and Loan Association in 1848, Prudential plc has moved on a lot since then. Set up to sell life insurance and loans to the middle and then the industrializing and urbanizing working classes, the company subsequently diversified into Europe and then North America with the purchase of Jackson National Life in around 1985. During its time as owner of Jackson, Prudential focused on building out a simple chassis-style product portfolio where customers could choose a variety of add-ons. The company also became renowned for its focus on building requisite internal capabilities to support its strong product offerings, including compelling technology and a large and well-trained sales personnel.

About BGNE BeiGene Ltd.

BeiGene Ltd is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. BeiGene's key cancer treatments are BRUKINSA (zanubrutinib), Bruton's tyrosine kinase (BTK) inhibitor, and TEVIMBRA (tislelizumab), an anti-PD-1 antibody. In addition, it has a diverse pipeline of novel therapeutics focusing on a range of malignancies, including AML, MDS, multiple myeloma, lung, gastrointestinal, breast, and gynecologic cancers. The Company operates in one segment: pharmaceutical products and is primarily located in the U.S. and the PRC. Key revenue is generated from the U.S.

Share on Social Networks: